Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018.

Abstract

Meropenem-vaborbactam is approved to treat hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), in Europe. Meropenem-vaborbactam activity was evaluated against 3,193 Pseudomonas aeruginosa and 4,790 Enterobacterales isolates causing pneumonia, including VAP, in hospitalized patients in the United States. Susceptibility testing was performed by using the broth microdilution method, and all carbapenem-resistant isolates were submitted for whole-genome sequencing. Meropenem-vaborbactam exhibited almost complete activity against Enterobacterales (>99.9% susceptible), including carbapenem-resistant Enterobacterales (CRE), and was also very active against P. aeruginosa isolates (89.5% susceptible).

• Authors: Cecilia G Carvalhaes, Dee Shortridge, Helio S Sader, Mariana Castanheira
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 64 Issue 3 (02 21 2020) ISSN: 1098-6596 [Electronic] United States
• PMID: 31907187 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 Carvalhaes et al.

Chemical References

• Anti-Bacterial Agents
• Boronic Acids
• vaborbactam
• Meropenem

Topics

• Anti-Bacterial Agents (pharmacology)
• Boronic Acids (pharmacology)
• Enterobacteriaceae (drug effects, genetics, pathogenicity)
• Hospitals
• Humans
• Meropenem (pharmacology)
• Microbial Sensitivity Tests
• Pneumonia (microbiology)
• Whole Genome Sequencing